🔗 Share this article World Health Organization Raises Concern Over Acute Lack of Weight-Loss Medications Fewer than a tenth of patients that would benefit from obesity jabs such as Wegovy are able to get them, warns the World Health Organization as it publishes its first recommendations on the therapies. Considering over a billion individuals worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication. Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "Our new guidance acknowledges that excess weight is a chronic disease that can be addressed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are key hurdles to universal access to the injections that can assist patients in reducing considerable body mass, notes the organization. Skinny Jab Shortage Despite the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, per the health organization. The advice urges countries and companies to increase access, by strategies including voluntary licensing. The intellectual property rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026. The Way Obesity Injections Function GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so people consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of beginning the weekly injections. Studies points to people may put most of the weight back on a year later of discontinuing the treatment, as their usual food cravings resume. Being carrying excess weight elevates your risk for developing medical conditions, like type 2 diabetes, heart disease, brain attack, and specific cancers. Obesity impacts individuals in every country and was linked to millions of fatalities worldwide in 2024, according to the WHO.
Fewer than a tenth of patients that would benefit from obesity jabs such as Wegovy are able to get them, warns the World Health Organization as it publishes its first recommendations on the therapies. Considering over a billion individuals worldwide now classified as obese, it is calling for increased and just availability to GLP-1 medication. Per estimates, in excess of 2,000,000,000 are projected to be obese by 2030 unless action is taken. "Our new guidance acknowledges that excess weight is a chronic disease that can be addressed with comprehensive and lifelong support," said its chief Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and distribution challenges are key hurdles to universal access to the injections that can assist patients in reducing considerable body mass, notes the organization. Skinny Jab Shortage Despite the present best projected scenario, the manufacturing of GLP-1 therapies would only suffice for approximately 100 million people – under 10% of those who need them, per the health organization. The advice urges countries and companies to increase access, by strategies including voluntary licensing. The intellectual property rights on a key compound – the primary ingredient of the drug Wegovy – is scheduled to end in multiple countries in 2026. The Way Obesity Injections Function GLP-1 drugs mimick a biological compound to reduce digestion speed, curb appetite and increase feelings of fullness so people consume fewer calories. Individuals typically begin shedding pounds in the initial weeks of beginning the weekly injections. Studies points to people may put most of the weight back on a year later of discontinuing the treatment, as their usual food cravings resume. Being carrying excess weight elevates your risk for developing medical conditions, like type 2 diabetes, heart disease, brain attack, and specific cancers. Obesity impacts individuals in every country and was linked to millions of fatalities worldwide in 2024, according to the WHO.